Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Revenue (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Revenue for 6 consecutive years, with $6000.0 as the latest value for Q4 2025.

  • Quarterly Revenue fell 45.45% to $6000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $36000.0 through Dec 2025, down 40.98% year-over-year, with the annual reading at $36000.0 for FY2025, 40.98% down from the prior year.
  • Revenue hit $6000.0 in Q4 2025 for Lyell Immunopharma, down from $15000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $48.4 million in Q4 2022 to a low of $3000.0 in Q3 2022.
  • Historically, Revenue has averaged $4.8 million across 5 years, with a median of $26000.0 in 2023.
  • Biggest five-year swings in Revenue: soared 1614.6% in 2022 and later tumbled 99.97% in 2023.
  • Year by year, Revenue stood at $2.8 million in 2021, then skyrocketed by 1614.6% to $48.4 million in 2022, then crashed by 99.97% to $13000.0 in 2023, then decreased by 15.38% to $11000.0 in 2024, then crashed by 45.45% to $6000.0 in 2025.
  • Business Quant data shows Revenue for LYEL at $6000.0 in Q4 2025, $15000.0 in Q3 2025, and $8000.0 in Q2 2025.